Delta, Canada

Vincent Duronio


Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 97(Granted Patents)


Location History:

  • Delta, CA (2005 - 2008)
  • Vancouver, CA (2005 - 2008)

Company Filing History:


Years Active: 2005-2008

Loading Chart...
4 patents (USPTO):Explore Patents

Title: Vincent Duronio: Innovator in Therapeutic Chemokine Receptor Antagonists

Introduction

Vincent Duronio is a prominent inventor based in Delta, California. He has made significant contributions to the field of therapeutic chemokine receptor antagonists, holding a total of four patents. His work focuses on innovative treatments for various medical conditions, including autoimmune diseases and cancer.

Latest Patents

Duronio's latest patents revolve around the use of CXCR4 antagonists. These inventions provide a variety of therapeutic applications, such as reducing interferon gamma production by T-cells and treating multiple sclerosis, cancer, and autoimmune diseases. The patents also detail methods of medical treatment involving the administration of a therapeutic dose of a CXCR4 antagonist in a pharmacologically acceptable formulation. Additionally, the inventions include therapeutic compositions that comprise a CXCR4 antagonist along with a pharmacologically acceptable excipient or carrier.

Career Highlights

Vincent Duronio is affiliated with the University of British Columbia, where he continues to advance research in his field. His innovative work has garnered attention for its potential to improve treatment options for patients suffering from serious health conditions.

Collaborations

Duronio has collaborated with notable colleagues, including Ian Clark-Lewis and Jiang-Hong Gong. These partnerships have contributed to the development and refinement of his therapeutic inventions.

Conclusion

Vincent Duronio's contributions to the field of therapeutic chemokine receptor antagonists highlight his commitment to advancing medical science. His innovative patents and collaborations position him as a key figure in the ongoing quest for effective treatments for complex diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…